C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) C12P 19/34 (2006.01) A61K 31/551 (2006.01)
Patent
CA 2541561
A method for predicting a negative symptom change in a subject during drug therapy is provided. The method comprises isolating genomic DNA from a sample of the subject, and genotyping a T5988C marker of GRIN2B gene. A GRIN2B 5988 T/T genotype is predictive of a negative symptom improvement in the subject in response to drug therapy. The drug therapy may be clozapine therapy. Also provided is a method of identifying a polymorphism in a nucleotide sequence of interest that is predictive of response to drug therapy comprising the steps of assessing negative symptom improvement in a plurality of subjects during the course of drug therapy, isolating a sample comprising DNA from each subject, genotyping one or more nucleotide sequences of interest in the DNA of each subject to identify one or more polymorphisms that exist in the one or more nucleotide sequences of interest, wherein correlation of a significant improvement of negative symptoms with one or more polymorphisms is predictive of response to drug therapy.
Kennedy James Lowery
Martucci Livia
Centre For Addiction And Mental Health
Gowling Lafleur Henderson Llp
LandOfFree
Predicting negative symptom change during drug treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Predicting negative symptom change during drug treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Predicting negative symptom change during drug treatment will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1846088